Study Phase 3

A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease

Trial Information

Generic NameInfliximabProduct NameREMICADE®Therapeutic AreaDigestive System DiseasesEnrollment108% Female49%% White100%
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberC0168T16Data PartnerJohnson & JohnsonCondition StudiedCrohn's DiseaseMean/Median Age (Years)38

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.